{"id":"W2141766413","doi":"10.1111/jvh.12346","title":"Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase <scp>II</scp>b and <scp>III</scp> studies","year":2014,"lang":"en","type":"article","venue":"Journal of Viral Hepatitis","topic":"Hepatitis C virus research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Salix Pharmaceuticals; Bristol-Myers Squibb Canada; Genentech; Vertex Pharmaceuticals; Janssen Biotech; Roche; GlaxoSmithKline; Novartis; Pfizer; AbbVie; Sanofi; Human Genome Sciences","keywords":"Simeprevir; Tolerability; Medicine; Internal medicine; Gastroenterology; Ribavirin; Rash; Placebo; Neutropenia; Adverse effect; Virology; Hepatitis C virus; Virus; Toxicity; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02496749,0.002007485,0.005156525,0.002997437,0.0002593503,0.002337099,0.0007548831,0.001250352,0.004705935],"category_scores_gemma":[0.01953872,0.001013373,0.0226768,0.003298355,0.0003521719,0.001120228,0.001094862,0.001134056,0.0006802363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074356,"about_ca_system_score_gemma":0.001156586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009677988,"about_ca_topic_score_gemma":0.002367494,"domain_scores_codex":[0.9843442,0.009995263,0.002663249,0.001233938,0.001433929,0.0003294586],"domain_scores_gemma":[0.9906406,0.003812932,0.003549512,0.0006263488,0.001191628,0.0001789396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.1689037,0.000178718,0.01238581,0.04992495,0.6864218,0.0001494409,0.0001070259,0.00156904,0.003354863,0.000162956,0.004402886,0.07243881],"study_design_scores_gemma":[0.06879357,0.01241145,0.0657881,0.004375376,0.8300537,0.0005309595,0.0001035022,0.001569371,0.002122504,0.0007184634,0.01338297,0.000150029],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2316903,0.7272644,0.008112055,0.001480806,0.001080474,0.005075511,0.01956356,0.0005020426,0.00523084],"genre_scores_gemma":[0.8800157,0.09273075,0.005709537,0.001927021,0.0009532949,0.002938107,0.01336784,0.0001582669,0.002199509],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02496749,"threshold_uncertainty_score":0.1320423,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02898080242485937,"score_gpt":0.3425990692856471,"score_spread":0.3136182668607877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}